Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sharon Benzeno Sells 11,034 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Sharon Benzeno sold 11,034 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $21.00, for a total value of $231,714.00. Following the sale, the insider directly owned 272,751 shares in the company, valued at approximately $5,727,771. This represents a 3.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sharon Benzeno also recently made the following trade(s):

• On Monday, June 29th, Sharon Benzeno sold 154,768 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $21.14, for a total value of $3,271,795.52.

Adaptive Biotechnologies Stock Performance

Shares of ADPT stock opened at $21.45 on Wednesday. Adaptive Biotechnologies Corporation has a 52 week low of $9.96 and a 52 week high of $21.64. The company’s 50 day moving average price is $15.66 and its two-hundred day moving average price is $15.74. The company has a market capitalization of $3.43 billion, a P/E ratio of -65.00 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. During the same quarter in the prior year, the firm earned ($0.20) earnings per share. The firm’s revenue was up 35.1% compared to the same quarter last year. Analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of large investors have recently modified their holdings of ADPT. Westfield Capital Management Co. LP acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at about $65,942,000. Price T Rowe Associates Inc. MD grew its stake in Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares in the last quarter. Invesco Ltd. increased its position in shares of Adaptive Biotechnologies by 248.8% during the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after purchasing an additional 2,216,595 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Adaptive Biotechnologies by 544.0% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after purchasing an additional 2,062,282 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ADPT has been the topic of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. JPMorgan Chase & Co. decreased their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Morgan Stanley dropped their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Guggenheim boosted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday. Finally, BTIG Research reaffirmed a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a research report on Wednesday, June 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.